Chrysalis Intelligence · Product Codes · OZN

OZN · C. Difficile Toxin Gene Amplification Assay

Microbiology · 4 clearances · 3 unique sponsors

Device class
Class II
Regulation 866.3130
Total clearances
4
2021-09-09 → 2025-02-28
Last 12 months
0
Unique sponsors
3
Definition

What is C. Difficile Toxin Gene Amplification Assay

Amplification assay for the detection of c. Difficile toxin genes from stool specimens of symptomatic patients.
Medical specialty
Microbiology
Review panel
MI
Regulation number
866.3130
Implant
N
Life-sustain / support
N
GMP exempt
N
Third-party review
N
Trend

Clearance volume by quarter

Players

Top sponsors in this product code

Sponsor Clearances Last 12 mo Most recent
Roche Molecular Systems, Inc. 2 0 2021-10-20
Vela Operations USA 1 0 2023-11-14
Cepheid® 1 0 2025-02-28
Reimbursement

Likely billing codes (AI-inferred · verify with billing)

Healthcare providers using this device would typically bill under these HCPCS Level II (alphanumeric) or CPT (5-digit) codes. Mapping inferred from device function by Claude Haiku; official descriptions pulled from the CMS HCPCS April 2026 quarterly file where available. Always verify with billing/coding teams before relying on these.

CodeTypeDescriptionConfidenceRationale
87493 CPT High Clostridium difficile toxin gene detection by amplification assay; standard C. difficile molecular testing code
Pulse

Most recent 510(k) clearances

DateK-numberSponsorDevice
2025-02-28 K243730 Cepheid® Xpert C. difficile/Epi
2023-11-14 K232092 Vela Operations USA Great Basin Toxigenic C. difficile Direct Test (CDF2)
2021-10-20 K212427 Roche Molecular Systems, Inc. cobas Cdiff nucleic acid test for use on the cobas Liat System
2021-09-09 K210385 Roche Molecular Systems, Inc. cobas Cdiff nucleic acid test for use on the cobas Liat System